Page last updated: 2024-10-17

bupropion and Psychoses

bupropion has been researched along with Psychoses in 13 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Research Excerpts

ExcerptRelevanceReference
"Bupropion was administered to a 45-year-old white man being treated for depression with psychosis."7.70Serum sickness induced by bupropion. ( Alao, AO; Armenta, WA; Yolles, JC, 1999)
"Data came from 8120 smokers willing to make a quit attempt, randomized to varenicline, bupropion, nicotine replacement therapy (NRT) or placebo in Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) between 30 November 2011 and 13 January 2015."5.27Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. ( Anthenelli, RM; Benowitz, NL; Evins, AE; Krishen, A; Lawrence, D; Maravic, MC; McRae, T; Russ, C; St Aubin, L; West, R, 2018)
" Lorcaserin (Belviq(®)), phentermine/topiramate combination (Qsymia(®)), and bupropion/naltrexone combination have been demonstrated to be effective for the treatment of obesity, as an adjunct to a reduced-calorie diet and physical activity, although their absolute safety has yet to be established with more widespread use or longer use."3.79Therapies for obesity and medication-associated weight gain. ( Howland, RH, 2013)
" Exposure to bupropion during pregnancy (OR = 3."3.76Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. ( Figueroa, R, 2010)
"Bupropion was administered to a 45-year-old white man being treated for depression with psychosis."3.70Serum sickness induced by bupropion. ( Alao, AO; Armenta, WA; Yolles, JC, 1999)
"Bupropion is an antidepressant drug also used as a smoking cessation aid, which inhibits norepinephrine and dopamine re-uptake."1.35Two acute psychotic episodes after administration of bupropion: a case of involuntary rechallenge. ( Baratta, A; Javelot, H; Javelot, T; Messaoudi, M; Nonnenmacher, C; Weiner, L; Westphal, JF, 2009)
"A 29-year old had been admitted to our institution with acute onset of schizophreniform psychosis after 5-day administration of sustained-release bupropion hydrochloride, which had been prescribed for nicotine withdrawal in a daily dosage of 300 mg."1.32[Acute psychosis after administration of bupropion hydrochloride (Zyban)]. ( Livak, V; Neumann, M; Paul, HW, 2004)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19903 (23.08)18.7374
1990's3 (23.08)18.2507
2000's3 (23.08)29.6817
2010's4 (30.77)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
West, R1
Evins, AE1
Benowitz, NL1
Russ, C1
McRae, T1
Lawrence, D1
St Aubin, L1
Krishen, A1
Maravic, MC1
Anthenelli, RM1
Fatemi, SH1
Yousefi, MK1
Kneeland, RE1
Liesch, SB1
Folsom, TD1
Thuras, PD1
Howland, RH1
Javelot, H1
Baratta, A1
Weiner, L1
Javelot, T1
Nonnenmacher, C1
Westphal, JF1
Messaoudi, M1
Figueroa, R1
Jaffe, R1
Leavitt, R1
Wind, T1
Neumann, M1
Livak, V1
Paul, HW1
Goode, DJ1
Manning, AA1
Clower, CG1
Stoll, AL1
Mayer, PV1
Kolbrener, M1
Goldstein, E1
Suplit, B1
Lucier, J1
Cohen, BM1
Tohen, M1
Yolles, JC1
Armenta, WA1
Alao, AO1
Fernandez, F1
Levy, JK1
Wright, G1
Galloway, L1
Kim, J1
Dalton, M1
Miller, L1
Stern, W1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 4, Randomized, Double-blind, Active And Placebo-controlled, Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks Varenicline Tartrate 1mg Bid And Bupropion Hydrochloride 150mg Bid For Smoking Cessation In Subjects With[NCT01456936]Phase 48,144 participants (Actual)Interventional2011-11-30Completed
Varenicline and Smoking Cessation in Schizophrenia[NCT01111149]Phase 224 participants (Actual)Interventional2009-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

CO-Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall)

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID33.5
Bupropion 150 mg BID22.6
NRT Patch23.4
Placebo12.5

CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID38.0
Bupropion 150 mg BID26.1
NRT Patch26.4
Placebo13.7

CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 12

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID29.2
Bupropion 150 mg BID19.3
NRT Patch20.4
Placebo11.4

CO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall)

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID21.8
Bupropion 150 mg BID16.2
NRT Patch15.7
Placebo9.4

CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID25.5
Bupropion 150 mg BID18.8
NRT Patch18.5
Placebo10.5

CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive)." (NCT01456936)
Timeframe: Week 9 through Week 24

Interventionpercentage of participants (Number)
Varenicline 1.0 mg BID18.3
Bupropion 150 mg BID13.7
NRT Patch13.0
Placebo8.3

"Clinical Global Impression of Improvement (CGI-I), No Change Rating by Visit"

"The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as normal, not at all ill on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as no change on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs." (NCT01456936)
Timeframe: Baseline to Week 24

,,,
Interventionpercentage of participants (Number)
Week 1 (N= 1986, 1974, 1986, 1982)Week 2 (N= 1934, 1936, 1927, 1926)Week 3 (N= 1880, 1892, 1880, 1863)Week 4 (N= 1860, 1856, 1858, 1834)Week 5 (N= 1828, 1816, 1822, 1802)Week 6 (N= 1816, 1808, 1820, 1773)Week 8 (N= 1758, 1756, 1755, 1738)Week 10 (N= 1717, 1707, 1715, 1675)Week 12 (N= 1558, 1572, 1540, 1492)Week 13 (N= 1612, 16081602, 1575)Week 16 (N= 1586, 1606, 1568, 1541)Week 20 (N= 1563, 1573, 1523, 1510)Week 24 (N= 1533, 1515, 1499, 1497)
Bupropion 150 mg BID93.290.889.888.086.586.583.681.775.176.776.775.072.3
NRT Patch94.690.588.787.185.585.182.880.472.275.273.972.271.1
Placebo95.191.287.986.385.484.181.979.271.374.973.471.771.1
Varenicline 1.0 mg BID94.290.888.386.685.785.282.480.672.975.974.273.471.8

7-Day Point Prevalence of Abstinence (Overall)

"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks

,,,
Interventionpercentage of participants (Number)
Week 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12Week 13Week 14Week 15Week 16Week 17Week 18Week 19Week 20Week 21Week 22Week 23Week 24
Bupropion 150 mg BID1.117.922.324.425.726.930.226.530.427.630.727.126.529.229.225.127.927.827.923.926.726.427.023.2
NRT Patch0.914.220.023.525.126.831.328.032.128.032.127.626.929.429.224.928.128.228.123.726.526.325.323.6
Placebo1.010.312.113.113.614.617.915.918.115.518.816.016.019.119.816.118.819.519.216.318.818.418.315.7
Varenicline 1.0 mg BID1.318.826.330.433.435.839.537.441.638.742.539.636.839.538.533.136.436.235.730.833.933.833.029.8

7-Day Point Prevalence of Abstinence, Non-psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks

,,,
Interventionpercentage of participants (Number)
Week 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12Week 13Week 14Week 15Week 16Week 17Week 18Week 19Week 20Week 21Week 22Week 23Week 24
Bupropion 150 mg BID1.021.326.627.729.831.435.231.034.931.034.130.530.733.533.228.531.931.331.227.530.329.930.626.0
NRT Patch1.215.522.125.927.830.435.131.434.831.134.930.429.932.032.428.131.431.731.226.329.329.028.327.0
Placebo1.511.413.614.514.915.919.216.719.016.920.817.817.220.421.318.220.120.820.818.220.120.320.317.4
Varenicline 1.0 mg BID1.720.930.034.338.441.044.442.347.142.446.644.441.144.543.837.240.740.939.935.138.138.737.633.6

7-Day Point Prevalence of Abstinence, Psychiatric History Cohort

"A responder to this endpoint requires the answer no to both questions 3 and 6 on the nicotine use inventory at that specific visit.~NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?" (NCT01456936)
Timeframe: 24 Weeks

,,,
Interventionpercentage of participants (Number)
Week 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12Week 13Week 14Week 15Week 16Week 17Week 18Week 19Week 20Week 21Week 22Week 23Week 24
Bupropion 150 mg BID1.214.618.121.321.822.725.422.126.024.327.423.922.625.025.321.924.024.524.720.423.222.923.520.4
NRT Patch0.713.017.921.122.423.327.524.629.425.029.424.924.026.826.021.824.824.725.125.123.723.622.220.1
Placebo0.59.210.711.812.413.416.615.017.214.017.214.214.817.818.313.917.418.217.617.617.516.516.414.0
Varenicline 1.0 mg BID1.016.822.726.628.530.834.832.736.235.138.635.032.734.733.429.132.331.731.626.629.729.128.526.1

Estimated NPS AE Rate (%), by Cohort

"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionpercentage of participants (Least Squares Mean)
Non-psychiatric cohort (N=3984)Psychiatric cohort (N= 4074)
Bupropion 150 mg BID2.446.62
NRT Patch2.315.20
Placebo2.524.83
Varenicline 1.0 mg BID1.256.42

HADS Total Score (Overall)

The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24

,,,
InterventionUnits on a scale (Mean)
Week 1 (N= 1989, 1976, 1985, 1987)Week 2 (N= 1938, 1937, 1931, 1929)Week 3 (N= 1882, 1891, 1881, 1867)Week 4 (N= 1858, 1854, 1863, 1831)Week 5 (N= 1829, 1815, 1820, 1797)Week 6 (N= 1816, 1807, 1821, 1771)Week 8 (N= 1755, 1754, 1755, 1736)Week 10 (N= 1717, 1709, 1716, 1669)Week 12 (N= 1562, 1571, 1548, 1491)Week 13 (N= 1610, 1608, 1603, 1570)Week 16 (N= 1579, 1602, 1566, 1537)Week 20 (N= 1555, 1569, 1525, 1509)Week 24 (N= 1528, 1512, 1495, 1487)
Bupropion 150 mg BID5.615.064.604.394.164.054.103.863.793.663.773.733.80
NRT Patch4.954.744.484.314.084.013.964.003.783.713.783.723.82
Placebo5.054.804.384.394.144.094.124.043.953.703.823.753.62
Varenicline 1.0 mg BID5.034.684.314.153.943.823.823.853.643.603.673.653.62

HADS Total Score, Psychiatric History Cohort

The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24

,,,
InterventionUnits on a scale (Mean)
Week 1 (N= 1026, 1017, 1015, 1015)Week 2 (N= 1005, 1004, 996, 995)Week 3 (N= 947, 961, 945, 926)Week 4 (N= 935, 938, 929, 908)Week 5 (N= 918, 918, 914, 895)Week 6 (N= 917, 914, 912, 874)Week 8 (N= 887, 893, 878, 859)Week 10 (N= 864, 865, 864, 823)Week 12 (N= 790, 803, 798, 749)Week 13 (N= 813, 812, 814, 763)Week 16 (N= 795, 805, 791, 748)Week 20 (N= 784, 784, 763, 737)Week 24 (N= 770, 764, 758, 729)
Bupropion 150 mg BID7.586.996.516.366.035.875.965.725.665.445.625.545.69
NRT Patch6.826.646.306.165.825.625.635.645.445.365.445.465.57
Placebo6.706.426.026.045.805.755.635.555.425.095.375.265.04
Varenicline 1.0 mg BID6.766.425.995.875.585.395.435.385.175.065.265.175.21

Hospital Anxiety and Depression Scale (HADS) Total Score, Non-psychiatric History Cohort

The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms. (NCT01456936)
Timeframe: Baseline to Week 24

,,,
InterventionUnits on a scale (Mean)
Week 1 (N= 984, 972, 989, 992)Week 2 (N= 961, 954, 963, 970)Week 3 (N= 935, 930, 936, 941)Week 4 (N= 923, 916, 934, 923)Week 5 (N= 911, 897, 906, 902)Week 6 (N= 899, 893, 909, 897)Week 8 (N= 868, 861, 877, 877)Week 10 (N= 853, 844, 852, 846)Week 12 (N= 772, 768, 750, 742)Week 13 (N= 797, 796, 789, 807)Week 16 (N= 784, 797, 775, 789)Week 20 (N= 771, 785, 762, 772)Week 24 (N= 758, 748, 737, 758)
Bupropion 150 mg BID3.583.072.642.362.242.182.161.961.831.851.901.931.87
NRT Patch3.062.842.632.462.322.402.282.332.012.012.091.972.01
Placebo3.383.202.772.772.482.482.642.572.462.382.342.312.25
Varenicline 1.0 mg BID3.262.912.612.402.292.232.172.292.072.112.052.102.01

Occurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study Endpoint

"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionpercentage of participants (Number)
Non-psychiatric cohort (N= 990, 989, 1006, 999)Psychiatric cohort (N= 1026, 1017, 1016, 1015)Overall (N= 2016, 2006, 2022, 2014)
Bupropion 150 mg BID2.26.74.5
NRT Patch2.55.23.9
Placebo2.44.93.7
Varenicline 1.0 mg BID1.36.54.0

Occurrence of Severe-only NPS AEs in the Primary Endpoint, by Cohort

"The primary safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionpercentage of participants (Number)
Non-psychiatric cohort (N= 990, 989, 1006, 999)Psychiatric cohort (N= 1026, 1017, 1016, 1015)Overall (N= 2016, 2006, 2022, 2014)
Bupropion 150 mg BID0.41.40.9
NRT Patch0.31.40.8
Placebo0.51.30.9
Varenicline 1.0 mg BID0.11.40.7

Occurrence of the Components of NPS AE Primary Endpoint (Overall)

The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below. (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
AnxietyDepressionFeeling AbnormalHostilityAgitationAggressionDelusionsHallucinationManiaPanic DisorderParanoiaPsychosisHomicidal IdeationSuicidal BehaviorSuicidal IdeationSuicide
Bupropion 150 mg BID54114012141020120230
NRT Patch670140922514041150
Placebo5600331102810210151
Varenicline 1.0 mg BID570035171677140150

Occurrence of the Components of Severe-only NPS AE Endpoint (Overall)

"The NPS AE endpoint was the occurrence of at least 1 treatment-emergent severe AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent severe AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
AnxietyDepressionFeeling AbnormalHostilityAgitationAggressionDelusionsHallucinationManiaPanic DisorderParanoiaPsychosisSuicidal BehaviorSuicidal IdeationSuicideHomicidal Ideation
Bupropion 150 mg BID5411120112122000
NRT Patch6701600001040101
Placebo5600210002211010
Varenicline 1.0 mg BID5700120020141100

Occurrence of the Components of the NPS AE Primary Endpoint, Non-psychiatric History Cohort

"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
Anxiety (severe)Depression (severe)Feeling abnormal (severe only)Hostility (severe)Agitation (moderate and severe)Aggression (moderate and severe)Delusions (moderate and severe)Hallucinations (moderate and severe)Mania (moderate and severe)Panic (moderate and severe)Paranoia (moderate and severe)Psychosis (moderate and severe)Homicidal ideation (moderate and severe)Suicidal behavior (moderate and severe)Suicidal ideation (moderate and severe)Suicide (moderate and severe)
Bupropion 150 mg BID10011130014100110
NRT Patch00011921021011120
Placebo30001130023000031
Varenicline 1.0 mg BID01001030100000000

Occurrence of the Components of the NPS AE Primary Endpoint, Psychiatric History Cohort

"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
Anxiety (severe)Depression (severe)Feeling abnormal (severe only)Hostility (severe)Agitation (moderate and severe)Aggression (moderate and severe)Delusions (moderate and severe)Hallucinations (moderate and severe)Mania (moderate and severe)Panic (moderate and severe)Paranoia (moderate and severe)Psychosis (moderate and severe)Homicidal ideation (moderate and severe)Suicidal behavior (moderate and severe)Suicidal ideation (moderate and severe)Suicide (moderate and severe)
Bupropion 150 mg BID441029914916020120
NRT Patch670021712313030030
Placebo26002280267210120
Varenicline 1.0 mg BID560025141577140150

Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Non-psychiatric History Cohort

"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
AnxietyDepressionFeeling abnormalHostilityAgitationAggressionDelusionsHallucinationsManiaPanicParanoiaPsychosisHomicidal ideationSuicidal behaviorSuicidal ideationSuicide
Bupropion 150 mg BID1001010001000100
NRT Patch0001200001000000
Placebo3000000001000011
Varenicline 1.0 mg BID0100010000000000

Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Psychiatric History Cohort

"The safety endpoint is the occurrence of at least one treatment emergent severe adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent moderate or severe adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint." (NCT01456936)
Timeframe: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants (Number)
AnxietyDepressionFeeling abnormalHostilityAgitationAggressionDelusionsHallucinationsManiaPanicParanoiaPsychosisHomicidal ideationSuicidal behaviorSuicidal ideationSuicide
Bupropion 150 mg BID4410110111010100
NRT Patch6700400000010010
Placebo2600210001000100
Varenicline 1.0 mg BID5600110020000110

Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Non-psychiatric History Cohort

"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants with positive responses (Number)
Suicidal Behavior (Screening lifetime)Suicidal Ideation (Screening lifetime)Suicidal Behavior (Baseline)Suicidal Ideation (Baseline)Suicidal Behavior (treatment emergent 12 weeks)Suicidal Ideation (treatment emergent 12 weeks)
Bupropion 150 mg BID9430104
NRT Patch7500013
Placebo6490116
Varenicline 1.0 mg BID6480007

Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Overall

"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants with positive responses (Number)
Suicidal Behavior (Screening lifetime)Suicidal Ideation (Screening lifetime)Suicidal Behavior (Baseline)Suicidal Ideation (Baseline)Suicidal Behavior (treatment emergent 12 weeks)Suicidal Ideation (treatment emergent 12 weeks)
Bupropion 150 mg BID15240006119
NRT Patch11838302123
Placebo12939814331
Varenicline 1.0 mg BID14338606034

Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Psychiatric History Cohort

"The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from wish to be dead to active suicidal ideation with specific plan and intent. Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides." (NCT01456936)
Timeframe: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.

,,,
Interventionparticipants with positive responses (Number)
Suicidal Behavior (Screening lifetime)Suicidal Ideation (Screening lifetime)Suicidal Behavior (Baseline)Suicidal Ideation (Baseline)Suicidal Behavior (treatment emergent 12 weeks)Suicidal Ideation (treatment emergent 12 weeks)
Bupropion 150 mg BID14335705115
NRT Patch11133302020
Placebo12334913225
Varenicline 1.0 mg BID13733806027

Depression

Beck Depression Inventory (BDI), a self-report rating inventory measuring characteristic attitudes and symptoms of depression consisting of 21 items with each item rated on a four point scale (0=not present to 3=severe). The accepted ranges are as follows: 0 to 9 indicates no depression, 10 to 18 indicates mild to moderate depression, 19 to 29 indicates moderate to severe depression and 30 to 63 indicates severe depression. (NCT01111149)
Timeframe: Week 12

Interventionunits on a scale (Mean)
Sugar Pill3.71
Varenicline8.6
Bupropion HCl5.4

Detectibility (d') of Continuous Performance Test

The value d' is a measure of the difference between the signal (non-X) and noise (X) distributions. As such, d' provides a means for assessing an individual's discriminative power since, in general, the greater the difference between the signal and noise distributions, the better the ability to distinguish and detect X and non-X stimuli. The lower the score, the better the detectability. Values shown below are for week 12. (NCT01111149)
Timeframe: Week 12

Interventionunitless (Mean)
Sugar Pill0.71
Varenicline1.32
Bupropion HCl1.09

Response Style Indicator (Beta) for CPT

Beta represents an individual's response tendency: Some individuals are cautious and choose not to respond very often. Conceptually, such individuals want to make sure they are correct when they give a response. Higher values of Beta reflect this response style. The emphasis is on avoiding commission errors. Other individuals respond more freely to make sure they respond to most or all targets, and they tend to be less concerned about mistakenly responding to a non-target. Lower values of Beta are produced by this response style. Values shown below were obtained at week 12. (NCT01111149)
Timeframe: Week 12

InterventionBeta (Mean)
Sugar Pill0.95
Varenicline1.41
Bupropion HCl2.92

Smoking Abstinence - Exhaled Carbon Monoxide

Exhaled carbon monoxide as a biochemical verification of smoking abstinence. Values below are for week 12. (NCT01111149)
Timeframe: Week 12

Interventionparts per million (Mean)
Sugar Pill21.14
Varenicline17
Bupropion HCl22.6

Smoking Abstinence - Number of Cigarettes Smoked

Number of cigarettes smoked at week 12 of the study by self-report. (NCT01111149)
Timeframe: Week 12

Interventionnumber of cigarettes smoked (Mean)
Sugar Pill19.71
Varenicline9.4
Bupropion HCl17.1

Variability of Standard Error - CPT

"Variability of Standard Error (VSE) is a measure of response speed consistency. VSE measures within respondent variability. That is, the amount of variability the individual shows in 18 separate segments of the Continuous Performance Test in relation to his or her own overall standard error. Although VSE is a different measure than Overall Standard Error, typically the two measures produce comparable results. The higher the VSE, the greater the inconsistency in the response speed. The values shown below are the VSE for Week 12." (NCT01111149)
Timeframe: Week 12

Interventionmilliseconds (Mean)
Sugar Pill11.05
Varenicline11.38
Bupropion HCl11.8

Vital Signs - Pulse

Pulse will be measured. The values below were measured at week 12 of the study. (NCT01111149)
Timeframe: Week 12

Interventionheart beats per minute (Mean)
Sugar Pill82.57
Varenicline87
Bupropion HCl89.2

Vital Signs - Weight

Weight will be measured for each participant. Values listed below are for week 12. (NCT01111149)
Timeframe: Week 12

Interventionlbs (Mean)
Sugar Pill218.39
Varenicline213.47
Bupropion HCl254.78

Abnormal Movements - AIMS

Abnormal Involuntary Movement Scale (AIMS), to assess abnormal involuntary movements associated with antipsychotic drugs. There are 10 questions, based on a five-point scale ranging from 0 (none) to 4 (severe). Items 11-14 are yes/no questions that have no impact on the score. The Total Score is the sum of questions 1-7 (minimum = 0; maximum = 28). The severity index consists of one question (item 8; rated 0=none to 4=severe) based on the rater's observation of abnormal movements The AIMS Global Score is the sum of three questions (each item rated 0=none to 4=severe) regarding abnormal movements overall (minimum score 0, maximum score 12). For the total score and subscores, the higher the score, the greater the severity of abnormal movements. Scoring is based on the chapter: Guy W (2000), Abnormal Involuntary Movement Scale (AIMS), in: Handbook of Psychiatric Measures (Rush AJ Jr, et al., eds). APA Publishing: Washington DC: pp. 166-167. (NCT01111149)
Timeframe: Week 12

,,
Interventionunits on a scale (Mean)
AIMS Total (Week 12)AIMS Severity Index (Week 12)AIMS Global Score (Week 12)
Bupropion HCl1.400.40.6
Sugar Pill0.7100
Varenicline10.20.2

Abnormal Movements - BAS and SAS

"Barnes Akathisia Scale (BAS), a widely-used measurement of drug-induced akathisia. It consists of 4 questions with questions 1-3 scored on a scale of 0-3 with 0=normal and 3=severe (minimum score 0, maximum score 9; while item 4 is a global clinical assessment of akathisia rated on a scale of 0 (normal) to 5 (severe). The higher the score on each subsclae, the greater the severity of akathisia.~Simpson-Angus Scale (SAS), a 10-item instrument used to evaluate patients experiencing neuroleptic-induced parkinsonism and other extrapyramidal side effects. Items are rated for severity on a 0-4 scale, with 0 being normal and 4 being severe. Minimum = 0; Maximum = 40. The higher the score, the greater the severity." (NCT01111149)
Timeframe: Week 12

,,
Interventionunits on a scale (Mean)
SAS (Week 12)BAS Items 1-3 (Week 12)BAS Item 4 (Week 12)
Bupropion HCl0.420.40.2
Sugar Pill0.20.570.29
Varenicline0.760.60.4

Abstinence Related Symptoms - WISDM

The Wisconsin Inventory of Smoking Dependence Motives (WISDM) consists of 68 items regarding smoking. Each item is rated on a scale of 1 (not true of me at all) to 7 (extremely true of me) leading to a minimum score of 68 and a maximum score of 476. The higher the score, the greater the dependence. Four of the items are grouped into a Craving subscale (minimum 4, maximum 28), the greater the score, the greater the craving. Five of the items are grouped into a Cognition subscale (minimum 5, maximum 35), the higher the score, the greater reliance on cigarette smoking for cognitive enhancement. WISDM scoring based on the original article by Piper et al., 2004. A multiple motives approach to tobacco dependence: the Wisconsin inventory of smoking dependence motives (WISDM-68). Journal of Consulting and Clinical Psychology 72:139-154. (NCT01111149)
Timeframe: Week 12

,,
Interventionunits on a scale (Mean)
WISDM Total (Week 12)WISDM Cognition (Week 12)WISDM Craving (Week 12)
Bupropion HCl270.623.218
Sugar Pill229.1411.5715.14
Varenicline229.415.414.2

Abstinence-related Symptoms - MNWS and FTND

"Minnesota Nicotine Withdrawal Scale (MNWS), a patient-reported measure of nicotine withdrawal symptoms and cravings. Eight items are listed, including craving for cigarettes, irritability, frustration, or anger, anxiety, etc scored on a five point scale from 0 (normal) to 5 (severe). Patients are asked for responses for the past 24 hours and past seven days (minimum 0, maximum 32; for each subscale). The higher the score, the greater the dependence. Additionally, one question (minimum score 1, maximum score 4 measures the individual's confidence in resisting strong urges to smoke. The higher the score on this question, the greater the individual's confidence in resisting smoking urges.~The Fagerstrom Test for Nicotine Dependence measures nicotine dependence and consists of six questions with a total minimum score of 0 and a maximum score of 10. The higher the score, the greater the dependence on nicotine." (NCT01111149)
Timeframe: Week 12

,,
Interventionunits on a scale (Mean)
FTND (Week 12)MNWS 24 Hour Total (Week 12)MNWS 7 day total (Week 12)MNWS Resistance (Week 12)
Bupropion HCl4.46.605.802.4
Sugar Pill4.867.299.142.71
Varenicline5.28.2113.4

General Psychopathology

Brief Psychiatric Rating Scale (BPRS), an 24-item scale measuring positive symptoms, general psychopathology, and affective symptoms commonly used for schizophrenia with each item rated on a scale of 1-7 with 1=not present and 7=severe. The minimum score is 24 and the maximum score is 168. We have used five subscales as recommended by Dingemans et al., 1995: Positive subscale (minimum score 6; maximum score 42); Negative subscale (minimum score 5; maximum score 35); Depressed subscale (minimum score 5; maximum score 35); Mania subscale (minimum score 6; maximum score 42); and Disorientation subscale (minimum score 2; maximum score 14) . For both the total score and the subscale scores, the higher the score, the greater the symptom severity. We used the BPRS version 4.0. Dingemans PMAJ, Linszen DH, Lenoir ME, Smeets RMW, 1995. Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Psychopharmacology 122:263-267. (NCT01111149)
Timeframe: Week 12

,,
Interventionunits on a scale (Mean)
BPRS Total - Week 12BPRS Positive Subscale - Week 12BPRS Negative Subscale - Week 12BPRS Mania Subscale - Week 12BPRS Disorientation Subscale - Week 12BPRS Depression Subscale - Week 12
Bupropion HCl31.687.4826.2
Sugar Pill308.1466.4327.43
Varenicline34.296.46.4210.4

Hit Reaction Time - CPT

The hit reaction time is the average speed of correct responses for the entire test given in milliseconds. The higher the score, the slower the speed. The standard error is a measure of response speed consistency. The higher the overall standard error, the greater inconsistency in the response speed. The values below were measured at week 12. (NCT01111149)
Timeframe: Week 12

,,
Interventionmilliseconds (Mean)
Hit Reaction Time (week 12)Hit Reaction Time Standard Error (Week 12)
Bupropion HCl63.818.79
Sugar Pill42.447.20
Varenicline67.616.96

Impulsivity and Inattention

Impulsivity and inattention will be measured using the continuous performance test. Individuals were tasked with 359 items divided six blocks (59 in block 1, 60 in blocks 2-6). Omissions result from the failure to respond to target letters. CPT% Omissions measures the percentage of responses that qualify as omissions made during the test. Higher scores indicate increased inattention. Commissions result from responses given to non-targets. CPT% Commissions measures the percentage of responses that qualify as commissions made during the test. Higher scores indicate increased inattention. Perseverations result from reaction time less than 100 ms. CPT% Perseveration % measures the percentage of responses that qualify as perseverations made during the test. The higher the score, the greater impulsivity. (NCT01111149)
Timeframe: Week 12

,,
InterventionPercentage of responses (Mean)
CPT % Omissions (Week 12)CPT % Commissions (Week 12)Perseveration % (Week 12)
Bupropion HCl2.4228.330.12
Sugar Pill5.6236.110.57
Varenicline0.68251.05

Negative Symptoms of Schizophrenia - SANS

Scale for the Assessment of Negative Symptoms (SANS) a well-established test, used to assess the presence of psychosis or negative symptoms of schizophrenia. It consists of 25 questions rated on a scale of 0 (none) to 5 (severe). With a total score range of 0 to 125 points. There are 6 subscales: Affective Flattening or Blunting - (minimum, 0; maximum 35); Inappropriate Affect (minimum, 0; maximum 5); Alogia (minimum 0; maximum 25); Avolition-Apathy (minimum 0; maximum 20); Anhedonia-Asociality (minimum 0; maximum 25); Attention (minimum 0; maximum 15). Each subscale (except for Inappropriate Affect) contains one additional question as a Global Rating - or overall measure for that particular subscale. The sum of these questions constitutes the Total Global Score (minimum 0, maximum 25). The global questions are included within the Total Composite score. In each case, the larger the score, the more severe the symptoms. (NCT01111149)
Timeframe: Week 12

,,
Interventionunits on a scale (Mean)
SANS Total Composite (Week 12)SANS Total Global (Week 12)SANS Affective Flattening (Week 12)SANS Alogia (Week 12)SANS Avolition (Week 12)SANS Anhedonia (Week 12)SANS Attention (Week 12)Inappropriate Affect (Week 12)
Bupropion HCl6.201.60.803.61.400.40
Sugar Pill5.861.711.570.7121.5700
Varenicline17.23.870.635.80.20.60

Positive Symptoms of Schizophrenia (SAPS)

Scale for the Assessment of Positive Symptoms (SAPS), a well-established test, used to assess the presence of psychotic symptoms of schizophrenia. There are 34 items rated on a scale of 0-5 with 0=none and 5=severe for a minimum score of 0 and a maximum score of 170. There are 4 subscales: Hallucinations (minimum score 0; maximum score 35); Delusions (minimum score 0; maximum score 65); Bizarre Behavior (minimum score 0; maximum score 25); Positive Formal Thought Disorder (minimum score 0; maximum score 45). Each subscale contains one additional question as a Global Rating - or overall measure for that particular subscale. The sum of these questions constitutes the Total Global Score (minimum 0, maximum 20). The values for the Global items are included in the Total Composite score. In each case, the higher the score, the greater the severity of symptoms. (NCT01111149)
Timeframe: Week 12

,,
Interventionunits on a scale (Mean)
SAPS Total Composite Score - Week 12SAPS Total Global - Week 12SAPS Hallucinations - Week 12SAPS Delusions - Week 12SAPS Bizarre Behavior - Week 12SAPS Thought Disorder - Week 12
Bupropion HCl10.61.833.80.43.4
Sugar Pill3.431.2921.4300
Varenicline71.22.24.200.6

Reduction in Smoking

Successful outcome will be defined as a 50% or greater reduction in self-reported cigarettes per day and a 30% greater reduction in carbon monoxide and cotinine levels. Measured at week 12 (NCT01111149)
Timeframe: Week 12

,,
Interventionparticipants (Number)
50% Reduction in Number of Cigarettes Smoked30% Reduction in Carbon Monoxide (Week 12)30% Reduction in Serum Cotinine (Week 12)30% Reduction in Urine Cotinine (Week 12)
Bupropion HCl1111
Sugar Pill2222
Varenicline2244

Side Effects

Side effects will be monitored by a physician and/or assistant and recorded (SEP). All patients withdrawn from the study because of emerging side effects will be followed until the side effects are resolved. Each item is scored based on a scale of 0=none; 1=mild; 2=moderate; and 3=severe. Below, the data are shown for participants experiencing symptoms on week 12 of the study. (NCT01111149)
Timeframe: Week 12

,,
Interventionparticipants (Number)
AnxietyDizzinessManiaAbnormal DreamsAbdominal PainHeadacheInsomniaNauseaPsychosisDry MouthChest PainIrregular Heart BeatWeakness/FaintingDiarrheaVomitingConstipationConfusionIrritabilityDroolingCold SweatsBlurred VisionLeg Pain/Cramps
Bupropion HCl0100101110001001111010
Sugar Pill3003031002002100010002
Varenicline3001130200000101101011

Smoking Abstinence - Serum/Urine Measurements

Measured by blood/urine tests for nicotine and its break-down product cotinine. (NCT01111149)
Timeframe: Week 12

,,
Interventionng/mL (Mean)
Serum Cotinine (Week 12)Serum Nicotine (Week 12)Urine Cotinine (Week 12)Urine Nicotine (Week 12)
Bupropion HCl213.815.4614.75412.75
Sugar Pill198.6722.57772820
Varenicline2076699.6613.25

Suicidality

The Columbia-Suicide Severity Rating Scale (C-SSRS), is a survey intended to quantify the severity of suicidal ideation and behavior. The questionaire for suicidal ideation consists of 5 questions with yes (1) /no (0) answers. If answers to questions 1 and 2 are no, questions 3-5 are skipped. Minimum of 0; Maximum of 5. The questionaire for suicidal behavior consists of seven questions rated 0 for no and 1 for yes. The minimum score is 0 and the maximum score is 7. In each case, the higher the score, the greater the severity. (NCT01111149)
Timeframe: Week 12

,,
Interventionunits on a scale (Mean)
Lifetime Suicidal Ideation (week 12)Lifetime Suicide Attempts (week 12)
Bupropion HCl0.40.4
Sugar Pill1.711.29
Varenicline0.81.2

Urge to Smoke - MNWS

The Minnesota Nicotine Withdrawal Scale (MNWS) includes two items where individuals are asked to 1) declare the percentage of time they had an urge to smoke (MNWS % Urge to Smoke); and 2) declare the percentage of time they had a strong urge to smoke (MNWS % Strong Urge). For each case, percentages range from 0% to 100% - the higher the percentage, the greater urge to smoke. (NCT01111149)
Timeframe: Week 12

,,
Interventionpercentage of time (Mean)
MNWS % Urge to Smoke (Week 12)MNWS % Strong Urge (Week 12)
Bupropion HCl4732.4
Sugar Pill36.4326.43
Varenicline4733

Vital Signs

blood pressure will be measured. (NCT01111149)
Timeframe: Week 12

,,
Interventionmm Hg (Mean)
Systolic Blood Pressure (Week 12)Diastolic Blood Pressure (Week 12)
Bupropion HCl128.474.8
Sugar Pill116.2976.71
Varenicline12278.4

Reviews

1 review available for bupropion and Psychoses

ArticleYear
Psychopharmacotherapy of psychiatric syndromes in asymptomatic and symptomatic HIV infection.
    Psychiatric medicine, 1991, Volume: 9, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antidepressive Agents; Anxiety Disorders; Bupropion; Depr

1991

Trials

4 trials available for bupropion and Psychoses

ArticleYear
Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES.
    Addiction (Abingdon, England), 2018, Volume: 113, Issue:8

    Topics: Adult; Age Factors; Anxiety Disorders; Bupropion; Double-Blind Method; Ethnicity; Female; Humans; In

2018
Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: a double-blind placebo and bupropion-controlled study.
    Schizophrenia research, 2013, Volume: 146, Issue:1-3

    Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzazepines; Bupropion; Double-Blin

2013
Comparison of bupropion alone and with haloperidol in schizo-affective disorder, depressed type.
    The Journal of clinical psychiatry, 1983, Volume: 44, Issue:7

    Topics: Adolescent; Adult; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; H

1983
Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects.
    The Journal of clinical psychiatry, 1985, Volume: 46, Issue:1

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Body Weight; Bupropion; Chroni

1985

Other Studies

8 other studies available for bupropion and Psychoses

ArticleYear
Therapies for obesity and medication-associated weight gain.
    Journal of psychosocial nursing and mental health services, 2013, Volume: 51, Issue:5

    Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined

2013
Two acute psychotic episodes after administration of bupropion: a case of involuntary rechallenge.
    Pharmacy world & science : PWS, 2009, Volume: 31, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delirium; Diagnosis, Dual (Psychiatry);

2009
Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring.
    Journal of developmental and behavioral pediatrics : JDBP, 2010, Volume: 31, Issue:8

    Topics: Adult; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Bipo

2010
QTc prolongation in multiple drug overdose.
    Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:3

    Topics: Adult; Bupropion; Drug Overdose; Fluoxetine; Humans; Long QT Syndrome; Male; Piperazines; Psychotic

2004
[Acute psychosis after administration of bupropion hydrochloride (Zyban)].
    Psychiatrische Praxis, 2004, Volume: 31 Suppl 1

    Topics: Acute Disease; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Hum

2004
Schizo-affective disorder: diagnostic criteria.
    The Journal of clinical psychiatry, 1984, Volume: 45, Issue:3

    Topics: Bupropion; Depressive Disorder; Humans; Manuals as Topic; Propiophenones; Psychotic Disorders

1984
Antidepressant-associated mania: a controlled comparison with spontaneous mania.
    The American journal of psychiatry, 1994, Volume: 151, Issue:11

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Dis

1994
Serum sickness induced by bupropion.
    The Annals of pharmacotherapy, 1999, Volume: 33, Issue:9

    Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Female; Humans; Middle Aged; Psycho

1999